3 Great Australian Founder Led Stocks With Revenue Growth Up To 37%

Rising bond yields have dragged global shares lower as investors reassess what risk is worth, which puts a sharper spotlight on Australian businesses where founders still call the shots. When markets get jumpy, many investors look for leaders whose own reputations and wealth are on the line. This article walks through three founder-led Australian stocks from our screener that show how that mindset can shape listed companies.

The three founder-led Australian stocks in the list below are just a starting sample. The full screen surfaced another 80 businesses where owner-operators are still shaping the narrative but are not covered here.

If you want to identify which of those founder-backed opportunities best fits your own playbook, head straight into the Founder-Led Companies screener.

Pro Medicus (ASX:PME)

Overview: Pro Medicus provides founder-led medical imaging software platforms like Visage 7 and Visage RIS/PACS that power radiology workflows for hospitals worldwide.

Operations: Pro Medicus generates about A$261.7 million from integrated healthcare software, with substantial contributions from Australia and North America.

Market Cap: A$16.7b

Pro Medicus matters for this founder-led screener because its leaders have spent years refining a single, mission-critical imaging platform that hospitals build workflows around.

"Pro Medicus has had a 100% customer renewal rate since 2009. Not one hospital has ever left."

The real test now is how that loyalty holds up if a single key assumption about future demand and pricing power shifts.

If that assumption proves wrong, you will want the full context from the full narrative for Pro Medicus, which explains where pricing power could accelerate or stall next.

Mesoblast (ASX:MSB)

Overview: Mesoblast develops founder-led mesenchymal cell therapies like Ryoncil and rexlemestrocel-L for severe inflammatory, cardiovascular, and chronic pain conditions.

Operations: Mesoblast generates about $120 million from developing and commercializing its allogeneic cellular medicines platform across late stage clinical and commercial programs.

Market Cap: A$2.6b

Mesoblast matters for a founder-led screen because Silviu Itescu has shaped the mesenchymal cell platform from inception, keeping product development tightly aligned with a long-term, owner-driven plan.

"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption."

What really tests that founder blueprint is how one key shift in demand across much larger indications ultimately filters through to margins.

That margin question is where Mesoblast gets interesting, and the full narrative for Mesoblast outlines how the FDA win, patent stack and cash needs could be decoupling or accelerating ahead.

Harvey Norman Holdings (ASX:HVN)

Overview: Harvey Norman Holdings runs founder-led big box retail and franchise chains plus a sizeable property and lending arm across several countries.

Operations: Harvey Norman Holdings generates roughly A$2.8b from international retail operations, led by New Zealand, Ireland, and Singapore and Malaysia segments.

Market Cap: A$5.1b

Harvey Norman Holdings puts founder leadership on full display, with Gerry Harvey still steering the retail brands that carry his name and shaping how the property portfolio supports that network.

"It is worth noting, however, that just over 20% of 2025 profit can be attributed to property revaluations, non-cash gains that can be volatile and are not recurring operational earnings."

What matters most now is how a shift in the balance between rental income and retail performance reshapes the earnings story investors focus on.

That shifting mix is exactly what the full narrative for Harvey Norman Holdings unpacks, showing where retail earnings, property gains and capital allocation could be accelerating or quietly masking risk.

Seeking Alternatives Before Momentum Flies

Fresh ideas move first. By the time the crowd notices a breakout, early entry is gone and prices are already flying. Scan these under-the-radar lists while it matters and consider acting sooner rather than later.

• Spot potential turnarounds early by scanning the 15 high quality undiscovered gems, curated to surface financially solid operators still flying mostly under the radar.
• Track income-focused opportunities with the 5 dividend fortresses, built to highlight higher-yield payers where cash returns drive a big part of the total story.
• Follow the buildout of future energy infrastructure through the 16 nuclear energy infrastructure stocks, which groups contractors, equipment suppliers, and related plays into one focused list.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com